Key Clinical Pearls for Evaluating Surgical Candidates, and Patient Preference, for the Port Delivery System With Ranibizumab
The Port Delivery System with ranibizumab (PDS) is an FDA–approved drug delivery system for the treatment of neovascular age-related macular degeneration (nAMD). The PDS is a refillable ocular implant for continuous delivery of a customized formulation of ranibizumab, surgically implanted in the superotemporal quadrant at the pars plana. This presentation describes key clinical pearls for the preoperative evaluation of PDS surgical candidates, and reports on patient preference for the PDS versus intravitreal injection.